article · Molecules
Alzheimer's disease is a widespread neurodegenerative disorder that currently lacks effective treatment options. Thymoquinone is known for its anti-inflammatory, antioxidant, and anti-cancer properties, but its role in Alzheimer's disease research has remained largely uncharacterised. An animal study evaluated the compound's effects on mice with scopolamine-induced neuronal damage, used as an experimental model for the disease. Behavioural evaluations using the Y-maze and pole climbing tests demonstrated improvements in memory and motor performance following treatment. Tissue and molecular analyses revealed that thymoquinone reduced amyloid beta deposition and modulated proteins and genes associated with the peroxisome proliferator-activated receptor gamma signalling pathway, alongside effects related to miR-9. These outcomes indicate that thymoquinone delivers multilevel neuroprotective effects, functioning through anti-inflammatory action and receptor pathway activation, which may help mitigate pathological changes linked to the condition.
Alzheimer's disease causes progressive cognitive decline and remains difficult to treat. Finding compounds that protect brain cells and reduce the accumulation of harmful proteins, such as amyloid beta, is vital. Demonstrating that thymoquinone can improve memory and motor outcomes in preclinical models provides valuable insights into how natural bioactive compounds might support the development of future neuroprotective therapies.
This research could inform early-stage drug discovery efforts targeted at neurodegenerative conditions, serving pharmaceutical developers exploring peroxisome proliferator-activated receptor gamma pathways. Because the findings are based entirely on an in vivo mouse model, the work represents very early-stage experimental research and remains distant from clinical application or commercial deployment.
AI-generated from the published abstract. Always read the original work before citing.
BACKGROUND: Alzheimer's disease (AD) is a common neurodegenerative disorder without effective treatment. Thymoquinone (TQ) has demonstrated potential in exhibiting anti-inflammatory, anti-cancer, and antioxidant characteristics. Despite TQ's neuroprotection effect, there is a scarcity of information regarding its application in AD research, and its molecular trajectories remain ambiguous. Thus, the objective of the current investigation was to examine the potential beneficial effects and underlying mechanisms of TQ in scopolamine (SCOP)-induced neuronal injury to mimic AD in vivo model. METHODS: Thirty mice were divided into normal, SCOP, and TQ groups. The Y-maze and pole climbing tests were performed to measure memory and motor performance. Afterwards, histopathological and immunohistochemical examinations were carried out. Furthermore, peroxisome proliferator-activated receptor gamma (PPAR-γ) signaling pathway-related proteins and genes were detected with an emphasis on the role of miR-9. RESULTS: TQ has the potential to ameliorate cognitive deficits observed in SCOP-induced AD-like model, as evidenced by the improvement in behavioral outcomes, histopathological changes, modulation of the expression pattern of PPAR-γ downstream targets with a significant decrease in the deposition of amyloid beta (Aβ). CONCLUSIONS: TQ provided meaningful multilevel neuroprotection through its anti-inflammatory and its PPAR-γ agonist activity. Consequently, TQ may possess a potential beneficial role against AD development.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.3390/molecules28186566
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
